Lv4
660 积分 2023-07-19 加入
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
3天前
已完结
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial
14天前
已完结
Original communication on a natural phosphocalcic complex of logical and real assimilation, the original preparation D. 52
2个月前
已关闭
A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma
2个月前
已完结
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)
2个月前
已完结
Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma
3个月前
已完结
Salvage Therapies After Anti‐BCMA CAR‐T Failure in Patients With Multiple Myeloma: A Meta‐Analysis of Response Rates
3个月前
已完结
Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization
4个月前
已完结
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma
4个月前
已完结
Aqueous suspensions of crystalline estrogenic substances. A comparative assay
4个月前
已完结
皖公网安备34019202002308
